Recurrent Respiratory Papillomatosis Clinical Trial
Official title:
Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis."
Recurrent respiratory papillomatosis (RRP) is the most common benign neoplasm of the larynx in the pediatric population. The impact of the disease on patients and families can be tremendous due to the need for frequent treatment. It would be highly beneficial to develop effective medical therapies as adjunctive measures to surgical ablation with the goal of reducing the frequency of reoccurrence.
The focus of the present study is to evaluate the usefulness of cidofovir injection in
diminishing the frequency and magnitude of papilloma recurrences in adult and pediatric RRP
patients. Briefly, patients will be randomized into either a treatment (cidofovir injection)
or a placebo group. The following measures will be made at each of 6 data collection time
points, over the course of one year: (1) tumor load, based upon a published staging system
for papilloma, (2) degree of respiratory obstruction for phonation, as assessed by phonation
threshold pressures, and (3) general health, on validated health inventories (SF12 and Voice
Handicap Index for adults; PedsQL (Trademarked) for children) and via measures of height
weight and days absent from school or daycare, where applicable, for children. A repeated
measures analysis will allow examination of time by treatment interactions to determine if
the cidofovir injection group has fewer, or less severe, recurrences than the placebo group.
Specifically, we will answer the following questions in this investigation:
1. Does cidofovir injection reduce the frequency of RRP recurrences?
2. Does cidofovir injection reduce the magnitude of RRP, as assessed with a proposed
staging system for RRP (Derkay et al., 1998) and measures of phonatory threshold
pressure?
3. Does cidofovir injection improve general health, as assessed by height, weight and days
absent from school in pediatric patients and health inventories (general health and
voice-related) in children and adults?
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02854761 -
Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)
|
Phase 1 | |
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 | |
Completed |
NCT01020747 -
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
|
Phase 1 | |
Completed |
NCT00038714 -
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Active, not recruiting |
NCT04724980 -
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04645602 -
Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement
|
Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Withdrawn |
NCT01058317 -
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis
|
Phase 2/Phase 3 | |
Withdrawn |
NCT00829608 -
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
|
Phase 0 | |
Completed |
NCT00550914 -
Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP
|
N/A | |
Not yet recruiting |
NCT01995721 -
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
|
Phase 3 | |
Completed |
NCT02217358 -
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
|
N/A | |
Completed |
NCT00571701 -
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Recruiting |
NCT02555800 -
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Completed |
NCT03707587 -
M7824 in People With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Completed |
NCT02859454 -
Avelumab for People With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Active, not recruiting |
NCT02632344 -
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
|
Phase 2 | |
Completed |
NCT02592902 -
Recurrent Respiratory Papillomatosis and Extraesophageal Reflux
|
N/A | |
Recruiting |
NCT06412172 -
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
|
||
Recruiting |
NCT03465280 -
Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)
|